Amgen (AMGN) Assets Average (2009 - 2026)
Amgen (AMGN) posted quarterly Assets Average of $91.5 billion for Q1 2026, up 1.04% year-over-year from $90.6 billion in Q1 2025, and up 1.31% quarter-over-quarter from $90.4 billion in Q4 2025.
Amgen (AMGN) Assets Average (2009 - 2026) Analysis & Trends
Amgen's Assets Average history runs 17 years deep, the most recent figure standing at $91.5 billion for Q1 2026.
- In Q1 2026, Assets Average rose 1.04% year-over-year to $91.5 billion; the TTM figure through Mar 2026 stood at $91.5 billion (up 1.04% YoY), while the FY2025 annual figure was $91.2 billion, down 3.48% from the prior year.
- Assets Average for Q1 2026 stood at $91.5 billion, up from $90.4 billion in the prior quarter.
- The five-year high for Assets Average was $95.1 billion in Q1 2024, with the low at $59.2 billion in Q2 2022.
- The 5-year median for Assets Average is $90.4 billion (2025), against an average of $83.3 billion.
- The sharpest annual moves came in 2023 and 2025: Assets Average jumped 51.06% in 2023, then fell 4.7% in 2025.
- Amgen's Assets Average stood at $64.4 billion in 2022, then soared by 45.7% to $93.8 billion in 2023, then declined by 2.65% to $91.4 billion in 2024, then retreated by 1.09% to $90.4 billion in 2025, then grew by 1.31% to $91.5 billion in 2026.
- Business Quant data shows AMGN's Assets Average at $91.5 billion in Q1 2026, $90.4 billion in Q4 2025, and $89.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.23 Bn | 630.47 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 469.32 Bn | 462.76 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 378.85 Bn | 371.71 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 302.78 Bn | 295.09 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.59 Bn | 252.69 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 236.50 Bn | 222.51 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 182.49 Bn | 179.31 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 161.62 Bn | 149.92 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.56 Bn | 101.39 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 55.10 Bn | 47.72 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.07 Bn |
| Mar 31, 2026 | 91.55 Bn |
| Dec 31, 2025 | 90.36 Bn |
| Sep 30, 2025 | 89.02 Bn |
| Jun 30, 2025 | 88.63 Bn |
| Mar 31, 2025 | 90.60 Bn |
| Dec 31, 2024 | 91.36 Bn |
| Sep 30, 2024 | 90.90 Bn |
| Jun 30, 2024 | 91.94 Bn |
| Mar 31, 2024 | 95.07 Bn |
| Dec 31, 2023 | 93.84 Bn |
| Sep 30, 2023 | 90.40 Bn |
| Jun 30, 2023 | 89.49 Bn |
| Mar 31, 2023 | 76.92 Bn |
| Dec 31, 2022 | 64.41 Bn |
| Sep 30, 2022 | 61.50 Bn |
| Jun 30, 2022 | 59.25 Bn |
| Mar 31, 2022 | 60.18 Bn |
| Dec 31, 2021 | 63.08 Bn |
| Sep 30, 2021 | 62.38 Bn |